The prognostic time dependence of intra-tumoural IFNγ mRNA and protein in patients with breast cancer followed for 14 years after surgery and radiotherapy, without subsequent systemic therapy
暂无分享,去创建一个
[1] H. T. Park,et al. Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response , 2017, Nature Communications.
[2] Nan Zhang,et al. PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer , 2017, International Journal of Clinical Oncology.
[3] R. Shamir,et al. Reduced changes in protein compared to mRNA levels across non-proliferating tissues , 2017, BMC Genomics.
[4] L. Owens,et al. Review of the recombinant human interferon gamma as an immunotherapeutic: Impacts of production platforms and glycosylation. , 2016, Journal of biotechnology.
[5] Zeming Liu,et al. Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis , 2016, PloS one.
[6] A. Butte,et al. Cross-tissue Analysis of Gene and Protein Expression in Normal and Cancer Tissues , 2016, Scientific Reports.
[7] P. Hertzog,et al. Antitumour actions of interferons: implications for cancer therapy , 2016, Nature Reviews Cancer.
[8] F. Annunziato,et al. The 3 major types of innate and adaptive cell-mediated effector immunity. , 2015, The Journal of allergy and clinical immunology.
[9] G. Merlino,et al. The Two Faces of Interferon-γ in Cancer , 2011, Clinical Cancer Research.
[10] M. Selbach,et al. Global quantification of mammalian gene expression control , 2011, Nature.
[11] Chia-Der Lin,et al. Increased programmed death‐ligand‐1 expression in human gastric epithelial cells in Helicobacter pylori infection , 2010, Clinical and experimental immunology.
[12] Gaëtan MacGrogan,et al. Variables with time-varying effects and the Cox model: Some statistical concepts illustrated with a prognostic factor study in breast cancer , 2010, BMC medical research methodology.
[13] Albert Koong,et al. Impaired interferon signaling is a common immune defect in human cancer , 2009, Proceedings of the National Academy of Sciences.
[14] David E Levy,et al. IFNgamma signaling-does it mean JAK-STAT? , 2008, Cytokine & growth factor reviews.
[15] D. Laune,et al. Oestrogen receptor negative breast cancers exhibit high cytokine content , 2007, Breast Cancer Research.
[16] Robert D. Schreiber,et al. Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.
[17] A. Harris,et al. REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British Journal of Cancer.
[18] D. Rimm,et al. X-Tile , 2004, Clinical Cancer Research.
[19] K. Omura,et al. The expression of B7-H1 on keratinocytes in chronic inflammatory mucocutaneous disease and its regulatory role. , 2004, Immunology letters.
[20] A. López-Rivas,et al. Interferon-γ Sensitizes Human Myeloid Leukemia Cells to Death Receptor-mediated Apoptosis by a Pleiotropic Mechanism* , 2001, The Journal of Biological Chemistry.
[21] E. Tartour,et al. Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas. , 1998, Journal of the National Cancer Institute.
[22] G. Shaw,et al. Translational blockade imposed by cytokine-derived UA-rich sequences. , 1989, Science.
[23] Oliver H. Lowry,et al. Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.
[24] Jianguo Feng,et al. Clinicopathological and prognostic significance of serum cytokine levels in breast cancer. , 2014, Clinical Laboratory.
[25] H. Fiegl,et al. Interferon-gamma expression is an independent prognostic factor in ovarian cancer. , 2004, American journal of obstetrics and gynecology.
[26] Lloyd J. Old,et al. and shape tumour immunogenicity , 2001 .